Athenex files definitive proxy statement for special stockholder meeting

Buffalo, n.y., oct. 11, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has filed a definitive proxy statement with the securities and exchange commission in connection with a special meeting of stockholders (the "special meeting") scheduled on november 22, 2022 (to be held virtually as a live webcast). the special meeting is being held to vote on three matters, including to effect an increase in the total number of authorized shares of common stock of the company, to effect a reverse stock split of the issued and outstanding shares of common stock, and to increase the number of shares available for issuance under the company's 2017 omnibus incentive plan. the company's board of directors has recommended that stockholders vote their shares “for” each of the proposals presented at the special meeting.
ATNX Ratings Summary
ATNX Quant Ranking